Minimal Residual Disease in Myeloma

Sustained MRD negativity for three years can guide discontinuation of LEN maintenance in myelomaПодробнее

Can MRD blood tests replace bone marrow biopsy? #asktheimfПодробнее

Best imaging to monitor multiple myeloma progression #asktheimfПодробнее

COMMANDER trial: iberdomide combinations to eliminate MRD after induction and autoSCT in myelomaПодробнее

Whole genome sequencing of cfDNA as a non-invasive method for MRD detection in multiple myelomaПодробнее

The association between MRD and PFS in myelomaПодробнее

FAQs From the International Myeloma Society Annual MeetingПодробнее

Investigating the use of mass spectrometry & NGF to measure MRD and predict outcomes in HR-SMMПодробнее

OncoAlert Session Round Up at #ASH24 in Multiple Myeloma: Advancing Minimal Residual Disease (MRD)Подробнее

Challenges that remain regarding the use of cfDNA for MRD detection in myeloma: cost and sensitivityПодробнее

Final results of the DART4MM study of daratumumab for MRD eradication in myelomaПодробнее

MILESTONE Trial: MRD Adapted Deferral of Transplant in Dysproteinemia | Susan Bal, MD | IMS 2024Подробнее

The impact of MRD in apheresis product in patients with myeloma undergoing autoSCTПодробнее

A trial investigating IberVd in transplant-ineligible newly diagnosed multiple myelomaПодробнее

Using MRD after autoSCT as a benchmark for consolidation strategies in myelomaПодробнее

Should MRD Guide Myeloma Treatment? A Debate. | Rahul Banerjee, MD and Sridevi Rajeeve, MD |IMS 2024Подробнее

MILESTONE trial results: MRD response-adapted deferral of autoSCT in newly diagnosed myelomaПодробнее

Standardizing MRD techniques after FDA approval as a surrogate endpoint in myeloma trialsПодробнее

Detecting Minimal Residual Disease | Dory Abelman, PhD(c) | IMS 2024Подробнее

Using MRD Adapted Strategy (MIDAS) to guide myeloma treatment | Sagar Lonial, MD, FACP | IMS 2024Подробнее